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Abstract
Background: The relatively short durations of the initial pivotal randomized placebo-controlled trials involving
atomoxetine HCl for the treatment of attention-deficit/hyperactivity disorder (ADHD) provided limited insight into
the time courses of ADHD core symptom responses to this nonstimulant, selective norepinephrine reuptake
inhibitor. The aim of this analysis was to evaluate time courses of treatment responses or remission, as assessed by
attainment of prespecified scores on the ADHD Rating Scale-IV-Parent Version: Investigator Administered and
Scored (ADHDRS-IV-PI) and the Clinical Global Impressions-ADHD-Severity (CGI-ADHD-S) scales, during up to 1 year
of atomoxetine treatment in children with ADHD.
Methods: Using pooled data from three Canadian open-label studies involving 338 children ages 6-11 years with
ADHD who were treated with atomoxetine for 3, 6 and 12 months, and survival analysis methods for interval-
censored data, we estimated the time to: 1) improvement and robust improvement defined by ≥25% and ≥40%
reductions from baseline ADHDRS-IV-PI total scores, respectively; and 2) remission using two definitions: a final
score of ADHDRS-IV-PI ≤18 or a final score of CGI-ADHD-S ≤2.
Results: The median time to improvement was 3.7 weeks (~1 month), but remission of symptoms did not occur
until a median of 14.3 weeks (~3.5 months) using the most stringent CGI-ADHD-S threshold. Probabilities of robust
improvement were 47% at or before 4 weeks of treatment; 76% at 12 weeks; 85% at 26 weeks; and 96% at 52
weeks. Probabilities of remission at these corresponding time points were 30%, 59%, 77%, and 85% (using the
ADHDRS-IV scale) and 8%, 47%, 67%, and 75% (using the CGI-ADHD-S scale). The change from atomoxetine
treatment month 5 to month 12 of -1.01 (1.03) was not statistically significant (p = .33).
Conclusions: Reductions in core ADHD symptoms during atomoxetine treatment are gradual. Although
approximately one-half of study participants showed improvement at 1 month of atomoxetine treatment,
remission criteria were not met until about 3 months. Understanding the time course of children’s responses to
atomoxetine treatment may inform clinical decision making and also influence the durations of trials comparing
the effects of this medication with other ADHD treatments.
Trial Registrations: clinicaltrials.gov: NCT00191633, NCT00216918, NCT00191880.
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Both psychostimulants and the selective norepinephrine
reuptake inhibitor atomoxetine HCl are recommended
psychopharmacological treatment options for children
diagnosed with attention-deficit/hyperactivity disorder
(ADHD), which is considered to be the most common
neurobehavioral disorder affecting children [1-3]. In
clinical practice, the onset of efficacy and times to
symptom improvement and remission during atomoxe-
tine treatment are different from those of stimulant
medications, leading to questions about the time
required to optimize atomoxetine treatment responses.
Our initial understanding of the time courses of ato-
moxetine responses was based on randomized placebo-
controlled clinical trials with relatively short durations
(typically ≤9 weeks) [4-8]. Notably, in these pivotal trials
symptom scores appeared to be still descending
(improving) at study completion. Hence, it was not pos-
sible to determine conclusively from these trials if
ADHD core symptoms could continue to decrease, and
if so, how quickly (or slowly) and to what extent. These
issues have implications for the evolving discussion
about ADHD symptom remission as a treatment goal;
that is, the concept that the target of ADHD treatment
should be minimal or no symptoms, a loss of diagnostic
status, and optimal functioning [9,10].
Although attainment of predefined thresholds on vali-
dated scales as a measure of symptom remission is a
useful barometer of improvement, the time courses of
responses to various treatments must be considered
when this outcome measure is used to compare inter-
ventions; this may be of marked importance when com-
paring treatments for ADHD–both pharmacological and
non-pharmacological (e.g. behavioral and psychoeduca-
tional interventions)–that have slower onsets of actions
compared with stimulants. Stimulants are notable within
the psychopharmacological armamentarium for the rela-
tive short time to peak clinical effects.
Improvements in ADHD symptoms have been defined
as ≥25% reductions (and robust improvement as ≥40%
reductions) on the ADHD Rating Scale-IV-Parent Ver-
sion: Investigator Administered and Scored (ADHDRS-
IV-PI) total score [4-11]. However, response definitions
based on percentage reduction in scale scores do not
take into account baseline symptom severity; for chil-
dren with very severe disease, robust changes may
represent substantial improvements yet leave them very
impaired, whereas children with less severe disease who
just meet diagnostic criteria may attain normalization
for age and gender after only modest percentage reduc-
tions in core symptoms. It is therefore helpful for inter-
preting symptomatic outcomes also to define
symptomatic remission. Operational definitions of symp-
tomatic remission include: 1) an ADHDRS-IV-PI total
score of ≤18 (average per-item score of ≤1), where 0 sig-
nifies “not [no symptoms] at all” and 3, “very much";
and 2) a Clinical Global Impressions-ADHD-Severity
(CGI-ADHD-S) scale score of ≤2, where 1 signifies “not
at all ill,” 2 “minimally ill,” and 7 “maximal, profound
impairment” [4-12].
The primary objective of this study was to determine
times to response and remission according to predefined
thresholds on the ADHDRS-IV-PI and CGI-ADHD-S
scales in children treated with atomoxetine at usual clin-
ical dosages [11,12]. To accomplish this aim, we esti-
mated the likelihood of response or remission with
atomoxetine as a function of time using pooled data
from three Canadian clinical trials with durations of up
to 1 year [13-15]. Equipped with a more detailed and
nuanced understanding of the time course of treatment
responses and remission with atomoxetine, clinicians
may be better able to: 1) educate (and calibrate the
expectations of) children and their parents/guardians/
teachers concerning time courses to different levels of
response or remission; 2) decide how long to continue a
medication trial; and/or 3) determine if (and when)
treatment augmentation or alteration might be needed.
By understanding the time courses of response and
remission, ADHD researchers may also be better posi-
tioned to design more clinically meaningful trials com-
paring the effects of atomoxetine, stimulants, and/or
other treatments.
Methods
Overview of studies analyzed
In this retrospective efficacy analysis, data were pooled
from three Canadian open-label studies [13-15]. These
trials assessed the effects of atomoxetine on both core
symptoms and a broad range of other outcome mea-
sures (the latter are not considered in this report). The
duration of treatment was 3 months in Study S012, 6
months in Study S013, and 1 year in Study LYCS.
Study Participants
Outpatient boys and girls aged 6 to 11 years (n = 212
in Study S012; n = 21 in Study S013; n = 105 in Study
LYCS) who had a diagnosis of ADHD according to the
Diagnostic and Statistical Manual of Mental Disorders
Text Revision (DSM-IV-TR) [16] were eligible. Mini-
mum symptom severity, as measured by the ADHDRS-
IV-PI total score, was ≥1.5 standard deviations (SD)
above age and gender norms. A slight difference
between trials was in study participant age ranges at
entry: 6 to 11 years in Study S012, 6 to 10 years in
Study S013, and 8 to 11 years in Study LYCS. All chil-
dren had normal intelligence based on investigator
judgment and a score of ≥85 if formal IQ testing was
conducted.
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der, psychosis, pervasive developmental disorders, con-
duct disorder, seizure disorder (other than febrile
seizures), or serious suicide risk. Eligible study partici-
pants also were not using other psychotropic medica-
tions and had no medical condition that would
contraindicate the use of atomoxetine.
Study designs
Study participant data were collected at child outpatient
clinics in Canada from August 2004 through June 2006.
Investigators were child psychiatrists or pediatricians.
All studies conformed to ethical principles of the
Declaration of Helsinki and all applicable laws, regula-
tions, and good clinical practices, and were approved by
ethics committees. Written informed consent was
obtained from parents/legal guardians and assent from
children. All eligible study participants completed base-
line assessments.
In Study LYCS, which commenced before atomoxetine
had been approved by Health Canada, atomoxetine treat-
ment was started at 0.5 mg/kg/day for the first 7 days,
then increased to approximately 1.2 mg/kg/day. An addi-
tional increase to the maximum of 1.4 mg/kg/day or 100
mg/day (whichever was less) based on efficacy and toler-
ability profiles was allowed [13]. In Studies S012 and
S013 [14,15], atomoxetine was titrated more slowly
(according to the approved Canadian atomoxetine pro-
duct monograph), to a maximum of 1.4 mg/kg/day as fol-
lows: 0.5 mg/kg/day for the first 10 days; 0.8 mg/kg/day
over the next 10 days; and 1.2 mg/kg/day for a minimum
of 10 days, with an increase to 1.4 mg/kg/day allowed
thereafter. All study participants were atomoxetine-naïve
at study entry. Studies also differed in study participants’
prior use of stimulants for ADHD. In Study LYCS, all
children entering were required to be stimulant-naïve,
whereas both stimulant-naïve and stimulant-treated chil-
dren were eligible for Study SO12 and Study SO13. Use
of psychotropic medications other than atomoxetine was
not permitted in any of the studies.
Measures
Efficacy measures in the present study were the
ADHDRS-IV-PI and the CGI-ADHD-S [11,12]. The tim-
ing of assessments varied across the studies. The
ADHDRS-IV-PI was assessed at baseline in all three stu-
dies and at: 1) months 1, 3, 5, 8, and 12 in Study LYCS;
2) months 1, 2, and 3 in Study S012; and 3) months 2
and 6 in Study S013. In all three studies, the CGI-
ADHD-S was assessed at baseline and again at week 2
with further assessments at: 1) months 1, 2, 3, 4, 5, 6, 8,
10, 12 in Study LYCS; 2) week 3 and months 1, 2, and 3
in Study S012; and 3) week 3 and months 1, 2, 4, and 6
in Study S013.
Symptom improvement was operationally defined a
priori as a ≥25% decrease from baseline on the
ADHDRS-IV-PI, and robust improvement as a ≥40%
decrease. Remission was defined in two ways: by a
threshold ADHDRS-IV-PI score ≤18 or a CGI-ADHD-S
score ≤2.
Statistical Analyses
Responses noted for the first time at a given visit are
unlikely to have occurred precisely at the moment of
the assessment; we can most accurately state that the
response occurred at some time between the current
and the most recent previous visit. In such cases, the
data are said to be “interval-censored” [17]. Some study
participants had not achieved a response by the time of
their final assessment; therefore, the time between base-
line and their last assessment served as a lower bound
on the time required to attain a response. Such data are
said to be “right-censored” [18]. Our pooled dataset
contained both interval- and right-censored data.
Survival analysis techniques, which utilize data from
all study participants to the point that they either
experience a response or are no longer available to be
followed, are the most appropriate methods for handling
censored data where the endpoint is the time to an
event of interest. Such methods allow data contributed
by study participants who withdrew early, or completed
the study but did not respond, to be included in the
analysis. These methods could accommodate data from
all three studies, regardless of the fact that the assess-
ment times varied between studies, and could also allow
inclusion of data from unscheduled visits and visits that
occurred outside of prescribed visit windows.
Because the time necessary to realize each of the four
treatment response criteria was of interest in the current
investigation, survival analysis methods were used.
Turnbull’s extension of the Kaplan-Meier curve to inter-
val-censored data was used to estimate the cumulative
probability of response over time (survivor function) as
well as to estimate the median time to response [17]. A
log-normal parametric model was used to assess the
univariate impact of baseline ADHDRS-IV-PI and base-
line CGI-ADHD-S on the time to each of the four end-
points of interest. A repeated-measures linear mixed
model was used to obtain the least-squares mean of
ADHDRS-IV-PI by month.
Results
Baseline characteristics
The pooled study sample comprised 249 (73.7%) boys
and 89 (26.3%) girls whose mean (standard error [SE])
age (overall) was 8.7 (0.08) years. Of study participants
in Study S012, 54.7% were stimulant-naïve compared
with 38.1% of those in Study S013 and 100% of those in
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on the ADHDRS-IV-PI and 4.8 (0.05) on the CGI-
ADHD-S (Table 1).
Subject disposition
Approximately 70% of study participants completed
each study: 68.6% in LYCS, 70.8% in S012, and 76.2% in
S013.
The most common reason for discontinuation in all
studies was lack of efficacy as perceived by the child/
caregiver or physician (10.7%), followed by adverse
events (6.5%). Five (1.5%) study participants were lost to
follow-up.
Outcomes
The median number of weeks from baseline to the last
available ADHDR-IV-PI assessment for the pooled stu-
dies was 13 weeks (~3 months). The follow-up time
between the baseline and last available assessment varied
according to the duration of each study. Table 2 reports
the mean (SE) and median (range) duration of follow-up
(weeks) by individual study, as well as for the combined
studies.
Atomoxetine treatment reduced ADHD symptoms
sharply during the first month and was associated with
further reductions in subsequent months. Mean
ADHDRS-IV-PI total scores leveled out at approxi-
mately month 5 (Table 3). The change from atomoxe-
tine treatment month 5 to month 12 of -1.01 (1.03) was
not statistically significant (p = .33).
As shown in Table 4, the median time to treatment
response varied markedly by criterion. The median time
to improvement according to the least stringent criter-
ion of treatment response was 3.7 weeks; the probability
of improvement was estimated at 60% at or before 4
weeks and 88% at or before 12 weeks. The median time
to a robust improvement was slightly greater (4.7
weeks), whereas the estimated probability of a robust
improvement was 47% at or before week 4 and 76% at
or before week 12 (Table 4).
Longer treatment intervals were required to meet defi-
nitions of symptom remission. The median time to
remission, defined as a total ADHDRS-IV-PI of ≤18, was
8.0 weeks, and the probability of remission did not reach
75% until approximately 24 weeks. To meet the most
rigorous criterion for remission (achieving a CGI-
ADHD-S score ≤2), the median time was 14.3 weeks.
For this endpoint, the probability of remission by 26
weeks was approximately 67% (Table 4).
Figure 1 presents the estimated cumulative probability
(Turnbull estimate) of meeting the response/remission
criteria at or before each month of atomoxetine treat-
ment; the curves for each of the four criteria are shown.
For each of the four treatment response criteria, the
estimated probability of achieving the endpoint at or
before week 16 of atomoxetine treatment was at least
50%, and by week 20 it was at least 60%.
Table 1 Summary of Baseline Characteristics
Characteristic Study
LYCS
(n = 105)
S012
(n = 212)
S013
(n = 21)
All
(N = 338)
Gender, male, n (%) 76 (72.4) 157 (74.1) 16 (76.2) 249 (73.7)
Age 9.3 (0.08) 8.5 (0.11) 8.0 (0.28) 8.7 (0.08)
ADHD subtype, n (%)
Combined 74 (70.5) 166 (78.3) 6 (28.6) 246 (72.8)
Inattentive 31 (29.5) 43 (20.3) 15 (71.4) 89 (26.3)
Hyperactive/impulsive 0 (0.0) 3 (1.4) 0 (0.0) 3 (0.9)
Stimulant-naïve, n (%) 105 (100.0) 116 (54.7) 8 (38.1) 229 (67.8)
ADHDRS-IV-PI 37.0 (0.84) 40.5 (0.52) 35.9 (1.13) 39.1 (0.43)
CGI-ADHD-S 4.6 (0.08) 4.8 (0.06) 4.9 (0.10) 4.8 (0.05)
ADHDRS-IV-PI = Attention-Deficit/Hyperactivity Disorder Rating Scale Parent
Version: Investigator Administered and Scored; CGI-ADHD-S = Clinical Global
Impression of ADHD Severity.
Mean (SE) or numbers (%).
Table 2 Summary of Subject Follow-up
Study
LYCS S012 S013 All
Weeks From Baseline to Last ADHDRS-IV-PI Assessment
N† 102 198 20 320
Mean (SE) 42.7 (1.63) 11.5 (0.23) 22.5 (1.64) 22.2 (0.97)
Median 51.3 12.9 25.9 13.3
Range 3.9-58.0 1.0-17.3 4.4-27.1 1.0-58.0
Weeks From Baseline to Last CGI-ADHD-S Assessment
N† 102 206 21 329
Mean (SE) 43.1 (0.15) 11.2 (0.25) 21.5 (1.9) 21.7 (0.96)
Median 51.3 12.7 25.9 13.3
Range 2.3-58.0 1.0-17.3 1.6-27.1 1.0-58.0
†Only study participants with both a baseline value and at least one post-
baseline value were included in this summary.
ADHDRS-IV-PI = Attention-Deficit/Hyperactivity Disorder Rating Scale Parent
Version: Investigator Administered and Scored; CGI-ADHD-S = Clinical Global
Impression of ADHD Severity.
Table 3 ADHDRS-IV-PI Least-Square (LS) Mean by Month
of Atomoxetine Treatment
Time Point N LS Mean (SE)
Day 0 335 39.12 (0.43)
Month 1 282 22.88 (0.65)
Month 2 179 21.00 (0.67)
Month 3 176 19.93 (0.67)
Month 5 85 17.83 (0.85)
Month 6 21 17.48 (1.79)
Month 8 81 17.27 (0.92)
Month 12 72 16.82 (0.99)
ADHDRS-IV-PI = Attention-Deficit/Hyperactivity Disorder Rating Scale Parent
Version: Investigator Administered and Scored.
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ADHDRS-IV-PI total score was a significant predictor
of the time to improvement, robust improvement, and
an ADHDRS-IV-PI ≤18, but not of a CGI-ADHD-S
score of ≤2. Higher baseline ADHDRS-IV-PI scores
(indicative of more severe ADHD symptomatology)
were associated with a shorter time to improvement
and robust improvement; whereas lower baseline
ADHDRS-IV-PI total scores were associated with a
shorter time to attain remission. The baseline value of
CGI-ADHD-S was also a significant predictor of time to
remission, with lower values (indicative of less severe
ADHD symptomatology) being associated with shorter
time required to achieve remission defined as a CGI-
ADHD-S score of ≤2.
Discussion
In this study, there was a progressive increase in the
likelihood that treatment met predefined thresholds for
response and remission with increasing time on atomox-
etine. Of interest, children’s ADHD symptoms contin-
ued to improve up to approximately 5 months.
Although there was symptomatic improvement as mea-
sured by the ADHDRS-IV-PI total score beyond this
time, the change was not statistically significant.
The present analysis of three Canadian open-label
clinical trials of atomoxetine produced clinically mean-
ingful findings that are consistent with data from two
recently reported European randomized, double-blind,
placebo-controlled studies that reported increased effi-
cacy of atomoxetine over time [19,20]. First, a Spanish
study of 151 treatment-naïve children and adolescents
(mean age = 10.3 years) with newly diagnosed ADHD
showed that reductions (improvements) in the
ADHDRS-IV-PI total score in the atomoxetine (vs. pla-
cebo) group first reached statistical significance at treat-
ment week 4; of importance, statistically significant
reductions in ADHD symptoms were evident between
weeks 6 and 12 [19]. Similarly, in a 10-week Swedish
study involving 99 stimulant-naïve children and adoles-
cents (mean age = 11.5 years), mean changes in the
ADHDRS-IV-PI total score from baseline in study parti-
cipants receiving atomoxetine in combination with psy-
choeducation (vs. placebo in combination with
psychoeducation) reached statistical significance at treat-
ment week 3 and continued to improve at each subse-
quent visit [20].
The gradual and progressive efficacy of atomoxetine in
treating core symptoms of ADHD, which was observed
in the present study, has potential implications for
understanding three previously reported studies compar-
ing the effects of atomoxetine to those of long-acting
stimulants [21-23]. The Strattera Adderall XR Rando-
mized Trial (St.A.R.T) was an analog classroom study
designed to assess the time course of treatment effect,
tolerability, and safety of mixed amphetamine salts
extended-release (MAS XR) compared with atomoxetine
in children with ADHD. The randomized double-blind
Table 4 Response Probabilities Over Time
Endpoint Probability That Endpoint Was Observed at or
Before:
Expected Week by Which This Percentage of Study Participants
Will Have Achieved Endpoint:
4 weeks 12 weeks 26 weeks 52 weeks 25% 50% 75%
Improvement 0.60
(0.38, 0.79)
0.88
(0.75, 0.95)
0.96
(0.85, 0.99)
1.00 – 3.7 7.2
Robust Improvement 0.47
(0.30, 0.65)
0.76
(0.60, 0.87)
0.85
(0.67, 0.94)
0.96
(0.87, 0.99)
3.6 4.7 12.0
Remission* 0.30
(0.16, 0.49)
0.59
(0.34, 0.79)
0.77
(0.48, 0.92)
0.85
(0.72, 0.93)
3.7 8.0 23.8
Remission** 0.08
(0.04, 0.16)
0.47
(0.26, 0.70)
0.67
(0.51, 0.80)
0.75
(0.60, 0.85)
5.3 14.3 52.3
†Probability with 95% confidence interval.
Remission using two definitions: *final score of ADHDRS-IV-PI ≤18, and **CGI-ADHD-S ≤2. ADHDRS-IV-PI = Attention-Deficit/Hyperactivity Disorder Rating Scale
Parent Version: Investigator Administered and Scored; CGI-ADHD-S = Clinical Global Impression of ADHD Severity.
Figure 1 Response Probabilities Over Time. Response using two
definitions: improvement = ≥25% reduction from baseline on the
ADHDRS-IV-PI and robust improvement = ≥40% reduction.
Remission using two definitions: a final score of (a) ADHDRS-IV-PI
≤18 or (b) CGI-ADHD-S ≤2. ADHDRS-IV-PI = ADHD Rating Scale
Parent Version: Investigator Administered and Scored; CGI-ADHD-S =
Clinical Global Impressions-ADHD-Severity.
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that the difference in effect size in this study indicated a
more robust treatment effect of MAS XR [23]. The
open-label study by Kemner and co-workers (2005) con-
cluded that treatment with osmotic-release oral system
methylphenidate (OROS MPH) exerted greater effects
on core ADHD symptoms compared with atomoxetine;
however, this was a short-term study (3 weeks) [22]. A
6-week active-comparator study also found that OROS
MPH was superior to atomoxetine for the total group,
but there were no differences in response rates for the
treatment-naïve subgroup [21].
Evidence from these comparator studies, the European
studies discussed above [19,20], and our analysis sup-
ports the clinical perception that atomoxetine is not the
ideal treatment for patients who require rapid control of
symptoms. However, it is potentially misleading to com-
pare effects of long-acting stimulants to those of ato-
moxetine based on short-term studies because
atomoxetine requires a longer treatment period to: 1)
attain an initial response and 2) achieve maximal possi-
ble reductions in ADHD symptoms. Long-term direct
comparison studies of atomoxetine and stimulants are
necessary to determine if the patterns of symptom
improvement with atomoxetine treatment differ from
those with stimulants in the long term as well as the
short term.
In our study, baseline illness severity substantially
influenced the time to meet predefined measures of
improvement. Children initiating atomoxetine therapy
with higher symptom severity scores met percentage
improvement criteria in a shorter time than children
starting with lower baseline symptom severity scores. In
contrast, children rated as less severely symptomatic on
the CGI-ADHD-S and ADHDRS-IV-PI achieved remis-
sion thresholds more rapidly. Of clinical interest, the
Integrated Data Exploratory Analysis study, a retrospec-
tive analysis of randomized controlled trials having 6- to
9-week durations, did not identify potential baseline
(moderator) predictors of response but did find that the
only predictor (on-treatment mediator) of a much
improved response at trial endpoint (≥40% decrease on
the ADHDRS-IV-PI) was being at least minimally
improved (≥25% but <40% decrease on the ADHDRS-
IV-PI) by treatment week 4 [24]. This finding of
improvement at 4 weeks’ predicting later improvement,
taken together with the possibility of continued
improvement over time (as found in the present Cana-
dian and European studies [13-15,19,20]), suggests that
monitoring for improvement at 1 month is valuable, as
is continued monthly monitoring to confirm the pre-
sence of progressive improvement in ADHD symptoms
that would justify continuation of atomoxetine
treatment.
Limitations
Our findings are most generalizable to Canadian children
ages 6 to 11.5 years who: 1) are of at least average intelli-
g e n c ea n dw h o s eA D H Ds y m p t o m sa r ew e l la b o v ea g e
and gender norms for severity; 2) do not have comorbid
conditions such as bipolar disorder, psychoses, pervasive
developmental disorders, conduct disorder, or serious
suicide risk; and/or 3) are treated with atomoxetine on
an outpatient basis. Most study participants (>70%) were
boys and had the combined subtype of ADHD. In addi-
tion, approximately two-thirds of enrolled children (and
all participants in the 1-year study) were previously
untreated with ADHD medications and therefore may
have been more responsive to medication than children
who had received, but failed, prior treatments. The trials
were all open label, and this study design feature may
have encouraged positive clinician bias in estimating
improvements; in Canada, it was considered unethical to
include a placebo arm in extended-duration studies of
ADHD. The results of the three open-label trials included
in our study may have been influenced by initial patient
selection and rater drift. Given the characteristics of our
sample, the designs of the studies, and the potential
advantages to children of clinical trial participation, it is
possible that the relatively high rates of response we
report with atomoxetine treatment will not be replicated
in usual clinical practice.
The slow upward titration of atomoxetine and the dif-
ferences in the titration schedules mandated by the
study protocols may have had some impact on early
response rates, but it is unlikely that the dosing of ato-
moxetine during the initial part of the study impacted
the major finding of the study, which was that there is
slow but progressive improvement over time during ato-
moxetine treatment long after titration is complete.
Only one of the primary studies (Study SO13) analyzed
herein included teachers’ evaluations, precluding inclusion
of teachers’ important perspectives on time courses to
response or remission with atomoxetine. In Study S013,
baseline symptom ratings completed by the teachers were
indicative of less severe symptoms than ratings completed
by parents, but the progressive improvements during this
6-month study showed that symptom decrements noted by
parents paralleled those of teachers [14]. In addition to
including data from a limited range of informants, our ana-
lyses were limited to measures of core ADHD symptoms.
Achieving a pre-defined ‘remission’ score on the CGI-
ADHD-S is indicative of improvement in ADHD sympto-
matology but does not necessarily mean that the child is
without impairments. Future clinical trials, especially those
comparing different treatments, should evaluate times to
achievement of thresholds or norms on other important
measures, including health-related quality-of-life and func-
tional/cognitive/neuropsychological outcomes.
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studies varied in length from 3-12 months and in addi-
tion approximately 30% of children did not complete
their study. Therefore, we chose methods of analysis
(survival curves) that do not require an equal length of
follow-up for each subject and that did not require that
all subjects complete the study. These methods estimate
response probabilities over time by using the data for
each subject up to the point that they either responded
or withdrew from the study. We don’t know the time by
which the drop-outs would have responded but each
participant contributes information: for example, a child
who discontinued at week 6 prior to responding pro-
vides information on the probability of achieving (or not
achieving) a response by week 6.
When interpreting such curves, it is essential to
understand both that there are declining numbers of
participants over time, and that the cumulative response
probability at a given time point is based not only on
those subjects still under observation, but also on the
pattern of response and withdrawals at all previous time
points. Thus the response probability at a certain time
depends directly on those still under observation, and
indirectly on those who withdrew or responded earlier.
Conclusions
Our findings concerning time courses of response and
remission with atomoxetine may inform future study
design and clinical decision making. From a clinical per-
spective, appropriate expectations should be set with
children and parents at the time of atomoxetine initia-
tion, because reductions in symptoms are gradual but
appear to progress over time. Designs of future compari-
son studies of medications to treat ADHD should con-
sider differences in time of onset of efficacy (and time
to peak response) between atomoxetine and stimulants
and/or other treatments.
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